Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | HTR7 | P34969 | 4/20 | 0.51 |
| ▸ | HTR1A | P08908 | 10/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | HTR6 | P50406 | 3/20 | 0.47 |
| ▸ | HTR2B | P41595 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HTR3A | P46098 | 3/20 | 0.47 |
| ▸ | HTR1D | P28221 | 1/20 | 0.47 |
| ▸ | HTR1B | P28222 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29893068 | 1.00 | KDR (0.53) | KDRHTR7HTR1ASLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL2849637 | 0.98 | KDR (0.51) | KDRHTR7HTR1ASLC6A2SLC6A4 | |
| SCHEMBL29557426 | 0.85 | KDR (0.53) | KDRHTR7HTR1ASLC6A2SLC6A4 | |
| SCHEMBL233938 | 0.85 | KDR (0.53) | KDRHTR7HTR1ASLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL29883289 | 0.83 | KDR (0.51) | KDRHTR7HTR1ASLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL4331979 | 0.83 | KDR (0.51) | KDRHTR7HTR1ASLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL5987897 | 0.83 | KDR (0.51) | KDRHTR7HTR1ASLC6A2SLC6A4 | |
| SCHEMBL6195611 | 0.83 | HTR3A (0.61) | HTR7HTR1ASLC6A4HTR6HTR2B | |
| SCHEMBL5716060 | 0.82 | ALDH1A1 (0.56) | HTR1AALDH1A1MAPTGAASMN1; SMN2 | |
| SCHEMBL23339696 | 0.81 | ALDH1A1 (0.45) | KDRHTR7HTR1AHTR6HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104046246-A | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PROD & CHEM | 2014-09-17 | — | — | CN | claimed |
| CN-103896962-B | One class thienopyridine esters derivative containing substituted piperazinyl and its production and use | 天津药物研究院 | 2016-09-14 | — | — | CN | disclosed |
| WO-2014192865-A1 | PHENYLPIPERAZINE DERIVATIVE | 大日本住友製薬株式会社 (JP) | 2014-12-04 | — | — | WO | disclosed |
| CN-104046246-A | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PROD & CHEM | 2014-09-17 | — | — | CN | disclosed |
| CN-103896962-A | Substituent piperazinyl-containing thienopyridine ester derivatives as well as preparation method and use thereof | TIANJIN INST PHARM RESEARCH | 2014-07-02 | — | — | CN | disclosed |
| US-20130035310-A1 | Piperidine and Piperazine Phenyl Sulfonamides as Modulators of Ion Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-07 | — | — | US | disclosed |
| US-20130035310-A1 | Piperidine and Piperazine Phenyl Sulfonamides as Modulators of Ion Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-07 | — | — | US | disclosed |
| US-20120184525-A1 | 1,2,3-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THIER USE FOR THE TREATMENT OF PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ADDEX PHARMA S.A. (CH) | 2012-07-19 | — | — | US | disclosed |
| WO-2005117882-A9 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEASE INHIBITORS | INCYTE CORP (US) | 2007-03-01 | — | — | WO | disclosed |
| EP-1622880-B1 | SUBSTITUTED DIHYDROCHINAZOLINES HAVING ANTIVIRAL PROPERTIES | BAYER HEALTHCARE AG (DE) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005117882-A2 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEASE INHIBITORS | INCYTE CORPORATION (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050250789-A1 | Hydroxamic acid derivatives as metalloprotease inhibitors | INCYTE CORPORATION | 2005-11-10 | — | — | US | disclosed |
| US-20040106623-A1 | Compounds specific for the human alpha1d adrenergic receptor and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-06-03 | — | — | US | disclosed |
| US-6706716-B2 | NERVOUS SYSTEM DISORDERS; HYPOTENSIVE AGENTS; INCONTINENCE | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-03-16 | — | — | US | disclosed |
| US-20020028760-A1 | Compounds specific for the human alpha1d adrenergic receptor and uses thereof | H. LUNDBECK A/S (DK) | 2002-03-07 | — | — | US | disclosed |
| EP-1100794-A1 | COMPOUNDS SPECIFIC FOR THE HUMAN $g(a) 1d? ADRENERGIC RECEPTOR AND USES THEREOF | Synaptic Pharmaceutical Corporation (US) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000004012-A9 | COMPOUNDS SPECIFIC FOR THE HUMAN α1d ADRENERGIC RECEPTOR AND USES THEREOF | SYNAPTIC PHARMA CORP (US) | 2000-10-26 | — | — | WO | disclosed |
| WO-2000004012-A1 | COMPOUNDS SPECIFIC FOR THE HUMAN α1d ADRENERGIC RECEPTOR AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106623-A1 | Compounds specific for the human alpha1d adrenergic receptor and uses thereof | ADRA1D, ADRA1A, ADRB1 | KDR 1247/4885HTR7 214/4885HTR1A 27/4885 |
| US-20120184525-A1 | 1,2,3-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THIER USE FOR THE TREATMENT OF PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | GRM2, GRM3, GRM1 | KDR 3131/4885HTR7 135/4885HTR1A 41/4885 |
| US-20130035310-A1 | Piperidine and Piperazine Phenyl Sulfonamides as Modulators of Ion Channels | TRPV1, TRPV5, TRPA1 | KDR 3655/4885HTR7 1643/4885HTR1A 1145/4885 |
| US-20020028760-A1 | Compounds specific for the human alpha1d adrenergic receptor and uses thereof | ADRA1D, ADRA1A, ADRB1 | KDR 725/4885HTR7 426/4885HTR1A 67/4885 |
| US-20050250789-A1 | Hydroxamic acid derivatives as metalloprotease inhibitors | MMP9, MMP17, MMP25 | KDR 1314/4885HTR7 1495/4885HTR1A 2489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.